Pulmonary Fibrosis Initiative

Pulmonary fibrosis (PF) is a chronic and progressive lung disease characterized by the scarring and thickening of lung tissue.

Phase I
Systems Architecture
Systems Architecture
Status: Completed
The Systems Architecture of Pulmonary Fibrosis Initiative is published as a web based tool open to public.
Phase II
Publications
Publications
Status: Completed
A peer-reviewed paper from the Pulmonary Fibrosis Initiative will be published for the community.
Phase III
In Silico Modeling
In Silico Modeling
Status: Completed
In this phase, in silico modeling will develop mathematical models of Pulmonary Fibrosis pathogenesis. This phase is in progress.
Phase IV
Combination Screening
Combination Screening
Status: Open
Combination Screening will be conducted to identify compounds targeting biological processes in Pulmonary Fibrosis pathogenesis.
Phase V
Patents
Patents
Status: Open
In this phase, a US patent will be filed for the newly discovered combination(s).
Phase VI
Licensing and Manufacturing
Licensing and Manufacturing
Status: Open
The Pulmonary Fibrosis Initiative will license and manufacture nutraceuticals to support treatment of Pulmonary Fibrosis.

Background on Pulmonary Fibrosis

Pulmonary fibrosis (PF) is a chronic and progressive lung disease characterized by the scarring and thickening of lung tissue. This scarring, also known as fibrosis, makes the lungs stiff and reduces their ability to expand and contract properly. As the fibrosis worsens over time, it becomes increasingly difficult for oxygen to pass from the lungs into the bloodstream, leading to shortness of breath. The causes of PF are diverse and often remain unknown (idiopathic pulmonary fibrosis). Known causes and associated conditions include exposure to certain environmental pollutants, some medications, radiation therapy, and connective tissue diseases like rheumatoid arthritis and scleroderma. Symptoms typically develop gradually and include shortness of breath (initially during exertion and later at rest), a dry, hacking cough, fatigue, and unexplained weight loss.   Unfortunately, there is currently no cure for pulmonary fibrosis, and the scarring is irreversible. However, various treatments are available to help manage symptoms, slow down the progression of the disease, and improve quality of life. These include medications, pulmonary rehabilitation to improve exercise tolerance and breathing techniques, and in some cases, lung transplantation. Early diagnosis and appropriate management are crucial for individuals living with pulmonary fibrosis.

Systems Architecture

The Systems Architecture of Pulmonary Fibrosis is published as a web based tool open to public . Click below to interact with the Systems Architecture

Publication

A peer-reviewed publication resulting from the Pulmonary Fibrosis Initiative will be published to the benefit of community.

In Silico Modeling

In this phase, the Pulmonary Fibrosis Initiative will conduct in silico modeling to identify and test the efficacy of natural compounds against the Fibrosis, Inflammation and Apoptosis. This phase is yet to begin.

Combination Screening

In this phase, combination screening will be performed to identify potential ingredient/compounds that target the biological process implicated in Pulmonary Fibrosis pathogenesis. This phase is yet to begin

Patents

The Open Science Institute® through its Pulmonary Fibrosis Initiative is moving towards getting patents for a revolutionary molecule that effectively combats pulmonary fibrosis disease, contributing breakthrough real solutions to society worldwide.

Licensing and Manufacturing

The Pulmonary Fibrosis Initiative plans to discover, develop, license and manufacture proprietary nutraceuticals to support treatment of Pulmonary fibrosis. Support our mission to bring this innovation to those who need it most. Please support this phase by donating to the Pulmonary Fibrosis Initiative

Health-product-label-09-10-2025